Last reviewed · How we verify

SOX Chemotherapy

The First Affiliated Hospital with Nanjing Medical University · FDA-approved active Small molecule Under review Quality 0/100

SOX Chemotherapy is a Combination chemotherapy regimen Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently FDA-approved for Gastric cancer, Colorectal cancer, Esophageal cancer. Also known as: SOX.

SOX is a combination chemotherapy regimen that uses S-1 (an oral fluoropyrimidine) and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.

SOX chemotherapy is a treatment for gastric cancer, specifically used in a study called RESONANCE-II, which combines the chemotherapy drug with S-1 and is administered in different cycles. The mechanism of SOX chemotherapy involves acting as a granulocyte colony-stimulating factor receptor agonist, a type of protein modality.

At a glance

Generic nameSOX Chemotherapy
Also known asSOX
SponsorThe First Affiliated Hospital with Nanjing Medical University
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

S-1 is a prodrug of 5-fluorouracil that inhibits thymidylate synthase and incorporates into DNA/RNA, while oxaliplatin is a platinum agent that forms DNA cross-links. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells. This combination is commonly used in gastric and colorectal cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SOX Chemotherapy

What is SOX Chemotherapy?

SOX Chemotherapy is a Combination chemotherapy regimen drug developed by The First Affiliated Hospital with Nanjing Medical University, indicated for Gastric cancer, Colorectal cancer, Esophageal cancer.

How does SOX Chemotherapy work?

SOX is a combination chemotherapy regimen that uses S-1 (an oral fluoropyrimidine) and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.

What is SOX Chemotherapy used for?

SOX Chemotherapy is indicated for Gastric cancer, Colorectal cancer, Esophageal cancer.

Who makes SOX Chemotherapy?

SOX Chemotherapy is developed and marketed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).

Is SOX Chemotherapy also known as anything else?

SOX Chemotherapy is also known as SOX.

What drug class is SOX Chemotherapy in?

SOX Chemotherapy belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is SOX Chemotherapy in?

SOX Chemotherapy is FDA-approved (marketed).

What are the side effects of SOX Chemotherapy?

Common side effects of SOX Chemotherapy include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Diarrhea, Peripheral neuropathy.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing